Product image of Linagliptin+metformin Stada (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Linagliptin+metformin Stada

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Linagliptin+metformin Stada (Metformin Hydrochloride, Linagliptin)

Linagliptin, the active ingredient in Linagliptin+metformin Stada, is a DPP‑4 inhibitor presented as a fixed‑dose oral tablet for oral use. It is combined with metformin hydrochloride, a biguanide, to treat type 2 diabetes mellitus in adults when diet and exercise alone are insufficient.

GNH India supplies Linagliptin+metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is distributed under strict regulatory compliance.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Linagliptin+metformin Stada is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia.
  • Type 2 diabetes mellitus: improves overall glycemic control when added to diet and exercise.
  • Inadequate control on metformin monotherapy: provides additional glucose lowering through DPP‑4 inhibition.
  • Combination therapy with other oral antidiabetics: offers synergistic effect to achieve target HbA1c levels.

How It Works

  • Linagliptin selectively inhibits dipeptidyl peptidase‑4 (DPP‑4), prolonging the activity of endogenous incretin hormones (GLP‑1 and GIP) and enhancing glucose‑dependent insulin secretion while suppressing glucagon release. Metformin hydrochloride reduces hepatic gluconeogenesis, improves peripheral insulin sensitivity, and increases glucose uptake in muscle, together lowering fasting and post‑prandial blood glucose concentrations.

Side Effects

The combination may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects

  • Gastrointestinal upset (nausea, abdominal discomfort)
  • Diarrhea
  • Headache
  • Mild hypoglycemia when used with sulfonylureas or insulin

Serious or Rare Side Effects

  • Lactic acidosis (especially in renal impairment)
  • Acute pancreatitis
  • Severe hypersensitivity reactions (e.g., angioedema, Stevens‑Johnson syndrome)
  • Hepatic failure
  • Persistent severe hypoglycemia

Precautions & Warnings

  • When prescribing Linagliptin+metformin Stada, clinicians should consider several precautionary measures.
  • Renal function: assess eGFR before initiation and monitor periodically.
  • Hepatic function: evaluate liver enzymes as metformin is contraindicated in severe hepatic disease.
  • Lactic acidosis risk: avoid in patients with significant renal impairment or conditions predisposing to hypoxia.
  • Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.
  • Drug interactions: review concomitant medications that may affect renal clearance or increase hypoglycemia.
  • Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Avoid Interactions

Linagliptin+metformin Stada can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

  • Severe renal impairment: increases risk of metformin‑associated lactic acidosis.
  • Concurrent use with iodinated contrast agents: may precipitate acute kidney injury.
  • Co‑administration with insulin or sulfonylureas: may cause profound hypoglycemia.

Moderate Interactions (Monitor Closely)

  • Cimetidine: can raise linagliptin plasma concentrations.
  • Diuretics (e.g., thiazides): may affect renal function and metformin clearance.
  • Alcohol intake: can potentiate metformin‑related lactic acidosis risk.

Frequently Asked Questions

Linagliptin+metformin Stada is prescribed for adults with type 2 diabetes mellitus to improve blood glucose control when diet, exercise, and metformin alone are insufficient. It combines a DPP‑4 inhibitor with a biguanide to target different pathways involved in glucose regulation.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades incretin hormones. By preserving incretin activity, it enhances glucose‑dependent insulin secretion and reduces glucagon release, thereby lowering post‑prandial blood glucose levels.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety in pregnancy and lactation has not been fully established. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin alone, the addition of linagliptin offers enhanced glucose control without the need for dose escalation of metformin. Unlike sulfonylureas, it has a lower intrinsic risk of hypoglycemia, and unlike some other DPP‑4 inhibitors, linagliptin does not require dose adjustment in mild to moderate renal impairment.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure the packaging is tightly closed to maintain product stability.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, particularly in patients with renal or hepatic impairment, and rare cases of acute pancreatitis. Severe hypersensitivity reactions such as angioedema or Stevens‑Johnson syndrome have also been reported and require immediate medical attention.

Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to either component, or those with a history of lactic acidosis should avoid this medication. It is also contraindicated in individuals with severe hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT